Fairmount Funds Management LLC’s activist stake in Apogee Therapeutics fell from greater than 5% to 0.0%, or 0.00 shares, after the merger. Shares were converted into the right to receive $135.11 per share in cash, while the voting agreement ended and the directors resigned at the merger’s effective time.

Key Highlights

  • Apogee Therapeutics’ directors, including Tomas Kiselak, resigned immediately before the Merger took effect.
  • The voting agreement automatically ended when the merger was completed and has no further force or effect.
  • Fairmount Funds Management LLC’s reported activist stake fell from greater than 5% to 0.0% after the merger.

Apogee Therapeutics, Inc. (NASDAQ: APGE) saw Fairmount Funds Management LLC’s activist position fall from greater than 5% to 0.0% on September 3, 2026. The reporting persons now hold 0.00 shares and no longer beneficially own securities of Apogee Therapeutics. The merger was completed on that date, with the company surviving as a Wholly Owned Subsidiary of Parent.

Fairmount Position Reaches Zero

Fairmount Funds Management LLC was listed alongside Fairmount Healthcare Fund II L.P. Peter Evan Harwin and Tomas Kiselak in the activist ownership group. Each reported 0.0% ownership after the transaction, with the listed share positions shown as 0.00. The ownership change followed the completion of the merger contemplated by an agreement dated June 18, 2026.

Cash Replaces Common Stock

Peter Evan Harwin exercised 42,208 vested director’s stock Options for 42,208 common shares on August 7, 2026.

Voting Agreement Ends

The voting agreement automatically terminated when the merger was consummated. It has no further force or effect. Apogee Therapeutics’ directors, including Tomas Kiselak, resigned immediately before the merger became effective and ceased serving on the board. The company continued as a wholly owned subsidiary of Parent following completion of the transaction.